EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Why Perfluorocarbon nanoparticles encounter bottlenecks in clinical translation despite promising oxygen carriers?

Anindita De, Jun-Pil Jee, Young-Joon Park

European Journal of Pharmaceutics and Biopharmaceutics · 2024-06 · 199 · 114292

DOI: 10.1016/j.ejpb.2024.114292 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2024-06. Verfasst von Anindita De und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Ajou University, 206 Worldcup-ro , Yeongtong-gu, Suwon-si 16499, Republic of Korea. Electronic address: aninditanirupa@gmail.com. Hauptthemen laut MEDLINE: Fluorocarbons, Nanoparticles, Oxygen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: Defense Acquisition Program Administration, Ministry of Trade, Industry and Energy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial Oxygen Carriers (AOCs) have emerged as ground-breaking biomedical solutions, showcasing tremendous potential for enhancing human health and saving lives. Perfluorocarbon (PFC)-based AOCs, in particular, have garnered significant interest among researchers, leading to numerous clinical trials since the 1980 s. However, despite decades of exploration, the success rate has remained notably limited. This comprehensive review article delves into the landscape of clinical trials involving PFC compounds, shedding light on the challenges and factors contributing to the lack of clinical success with PFC nanoparticles till date. By scrutinizing the existing trials, the article aims to uncover the underlying issues like pharmacological side effects of the PFC and the nanomaterials used for the designing, complex formulation strategy and poor clinical trial designs of the formulation. More over each generation of the PFC formulation were discussed with details for their failure in the clinical trials limitations that block the path of PFC-based AOCs' full potential. Furthermore, the review emphasizes a forward-looking approach by outlining the future pathways and strategies essential for achieving success in clinical trials. AOCs require advanced yet biocompatible single-componentformulations. The new trend might be a novel drug delivery technique, like gel emulsion or reverse PFC emulsion with fluoro surfactants. Most importantly, well-planned clinical trials may end in a success story.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluorocarbonsNanoparticlesOxygenHumansAnimalsClinical Trials as TopicTranslational Research, BiomedicalDrug Carriers

Stichwörter der Autor:innen

Artificial blood carriersChallenges of PFC-AOCsClinical TrialsPerfluorocarbon nanoparticlescommercial PFCs

Substanzen

FluorocarbonsOxygenDrug Carriers

Autor:innen und Institutionen

  • College of Pharmacy, Ajou University, 206 Worldcup-ro , Yeongtong-gu, Suwon-si 16499, Republic of Korea. Electronic address: aninditanirupa@gmail.com.
  • College of Pharmacy, Chosun University, 309 Pilmun-daero, Dong-gu, Gwangju 61452, Republic of Korea.
  • College of Pharmacy, Ajou University, 206 Worldcup-ro , Yeongtong-gu, Suwon-si 16499, Republic of Korea; Research Center, IMDpharm Inc., 17 Daehak 4-ro, Yeongtong-gu, Suwon-si 16226, Korea. Electronic address: parkyj64@…

Förderung

  • Defense Acquisition Program Administration
  • Ministry of Trade, Industry and Energy

Zitieren

APA

De, A., Jee, J. P., & Park, Y. J. (2024). Why Perfluorocarbon nanoparticles encounter bottlenecks in clinical translation despite promising oxygen carriers?. European Journal of Pharmaceutics and Biopharmaceutics, 199, 114292. https://doi.org/10.1016/j.ejpb.2024.114292

Vancouver

De A, Jee JP, Park YJ. Why Perfluorocarbon nanoparticles encounter bottlenecks in clinical translation despite promising oxygen carriers?. European Journal of Pharmaceutics and Biopharmaceutics. 2024;199:114292. doi:10.1016/j.ejpb.2024.114292

BibTeX
@article{De2024,
  author = {De, Anindita and Jee, Jun-Pil and Park, Young-Joon},
  title = {Why Perfluorocarbon nanoparticles encounter bottlenecks in clinical translation despite promising oxygen carriers?},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2024},
  volume = {199},
  pages = {114292},
  doi = {10.1016/j.ejpb.2024.114292}
}
Kostenlos starten →